Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

MicroRNAs in COPD: small molecules with big potential

Brian D. Hobbs, Kelan G. Tantisira
European Respiratory Journal 2019 53: 1900515; DOI: 10.1183/13993003.00515-2019
Brian D. Hobbs
Channing Division of Network Medicine and Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Brian D. Hobbs
  • For correspondence: rebdh@channing.harvard.edu
Kelan G. Tantisira
Channing Division of Network Medicine and Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

MicroRNA research in COPD can help explain the observed heterogeneity, not only in clinical presentation, but also in treatment response, particularly as it relates to inhaled corticosteroids http://ow.ly/HbYo30o7lIt

Micro ribonucleic acids (microRNAs or miRNAs) are small (∼22 nucleotide in length) non-protein-coding regulatory RNAs that have the potential to impact the development and progression of nearly all human diseases through interactions with messenger RNAs (mRNAs) [1]. MicroRNAs are transcribed from non-protein-coding regions of the genome into hairpin structures in the nucleus of cells and then are exported into the cytoplasm. The mature miRNA complexes can act within the cell or be secreted into the extracellular compartment to facilitate cell–cell communication. With partial miRNA–mRNA pairing, the target mRNA will be translationally repressed (less protein is made from the mRNA). With more complete miRNA–mRNA pairing, the mRNA will be sliced and silenced (i.e. no protein will be made) (figure 1). Any single miRNA can potentially target and repress hundreds of mRNAs [2]. These broad networks of miRNA–mRNA interactions allow a single miRNA to potentially impact a broad range of biological processes. Knockdown of miRNAs in mice has illustrated the potential impact of miRNAs in both contributing to and protecting from respiratory diseases [1].

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

MicroRNA–mRNA interactions. With partial microRNA–mRNA pairing, the translation of mRNA to protein is repressed through a variety of mechanisms. With complete complementarity of microRNA and mRNA, the mRNA will be cleaved and degraded. Thus, the target mRNA is silenced and cannot make protein. Reproduced with permission from the publisher [1].

Chronic obstructive pulmonary disease (COPD) is a heterogenous disease, not only in clinical presentation [3], but also in the variable response to therapy, particularly inhaled corticosteroids (ICS) [4]. Over the past ∼10 years, microRNA research in COPD has advanced our understanding of the role miRNAs may play in contributing to the phenotypic heterogeneity of COPD. MicroRNA expression studies in lung tissue, specific lung cell types, peripheral blood and immune cells have associated a number of miRNAs with COPD [5–7] as well as with COPD-related phenotypes, such as emphysema [8] and the asthma–COPD overlap syndrome [9]. Beyond evaluating miRNAs in isolation, several investigators have leveraged the negative regulatory relationship between miRNAs and mRNAs to build networks of miRNA–mRNA interactions that are associated with COPD [10]. Network-based investigations have the advantage of offering more immediate follow-up of the functional implications of miRNAs acting through specific mRNAs in contributing to COPD pathobiology. Additional studies of microRNA differential expression and miRNA–mRNA network interactions in COPD and COPD-related phenotypes are needed to validate prior findings and help describe the functional contribution of miRNAs to COPD phenotypic heterogeneity. Despite growing research in contributions of microRNAs to COPD pathobiology, little research to date has addressed the variable responses of COPD patients to available therapeutics.

In the current issue of the European Respiratory Journal, Faiz et al. [11] report the results of a genome-wide microRNA analysis assessing the changes in microRNA profiles of bronchial biopsies from persons with moderate-to-severe COPD following 6- and 30-month treatment with an ICS. The investigators performed staged investigations of the association of 230 measured miRNAs with ICS treatment, showing four miRNAs altered in the bronchial biopsies of persons with COPD following 6- and 30-month treatment with ICS. Of these four miRNAs, miR-320d was highlighted, as multiple lines of corollary external evidence reinforced the potential role of miR-320d in modulating the therapeutic response to ICS. First, miR-320d showed increased expression in bronchial biopsies after 6- and 30-month ICS treatment compared to placebo. Further, the predicted mRNA targets of miR-320d were significantly decreased at 6 months following ICS treatment. In a separate dataset, the predicted mRNA targets of miR-320d were increased in bronchial brushings of COPD cases compared to controls, which suggests a possible therapeutic role for suppression of miR-320d mRNA targets. In vitro fluticasone treatment of epithelial cells demonstrated a significant miR-320d upregulation, which was consistent with the in vivo microarray results. A pathway analysis suggested miR-320d mRNA targets were enriched in gene sets associated with cytokine production. Further, a network-based analysis of publicly available data highlighted IL-1β as a “hub” in a network of genes associated with cigarette smoke exposure. These bioinformatic analyses directed a series of in vitro functional studies and allowed the investigators to propose that in the setting of cigarette smoke exposure, miR-320d has an anti-inflammatory role mediated by suppression of NF-κB activity.

The work presented by Faiz et al. [11] has several strengths. First, the investigators utilised a series of staged investigations (including validation in both humans and cell culture) to avoid carrying false-positive associations from the primary genome-wide microRNA analysis into downstream functional analyses. Second, by evaluating overlapping microRNA and mRNA data, the authors were able to capture regulatory consequences of differences in miRNA expression, which help them to design functional studies for miR-320d. Finally, the investigators carried their primary findings from initial discovery, through functional studies, to a proposed mechanism of action. One limitation of the proposed mechanism of action of miR-320d is the dependence on cigarette smoke-induced inflammation, in which not all subjects in the discovery of miR-320d association with ICS treatment were current smokers. A stratified analysis of current and former smokers would help to determine if the observed differences in miR-320d expression between placebo and ICS treatment is modified by smoking. From a broader perspective, none of the microRNAs differentially expressed by ICS in the Faiz et al. [11] study overlap with those from bronchial cells of ICS-treated asthmatic patients [12, 13], though differences in study design, sample size, and ICS type, dose and duration were present. The question remains, is there a global set of miRNAs involved in the regulation of glucocorticoid sensitivity and resistance, or will disease-specific steroid “insensitivity” states necessitate distinct miRNA-mediated therapeutics?

As noted by the investigators, further functional work, possibly in mouse models of COPD, needs to be performed to investigate the immunomodulatory role of miR-320d. Short of further validation and functional work, the proposed function of miR-320d in ICS-mediated immunomodulation by Faiz et al. [11] lays a foundation for translational research. For instance, a panel of miR-320d gene targets is a potential biomarker for ICS response, in which the relative upregulation of miR-320d targets in COPD patients might predict a more robust response to ICS. Alternatively, miR-320d could be directly assessed, in which relatively higher levels of miR-320d in COPD patients may predict a poor response to ICS. In the future, if the role of miR-320d related response to ICS is confirmed in the airways and characterised, a miR-320d mimic could be investigated as either an alternative or adjunctive therapy to ICS in COPD.

Footnotes

  • Conflict of interest: B.D. Hobbs has nothing to disclose.

  • Conflict of interest: K.G. Tantisira has nothing to disclose.

  • Support statement: B.D. Hobbs is supported by NIH K08 HL136928 and the Parker B Francis Research Opportunity Award. K.G. Tantisira is supported by NIH R01 HL127332 and R01 HL129935. Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received March 11, 2019.
  • Accepted March 13, 2019.
  • Copyright ©ERS 2019
https://www.ersjournals.com/user-licence

References

  1. ↵
    1. Bartel DP
    . Metazoan MicroRNAs. Cell 2018; 173: 20–51.
    OpenUrlCrossRef
  2. ↵
    1. Hendrickson DG,
    2. Hogan DJ,
    3. McCullough HL, et al.
    Concordant regulation of translation and mRNA abundance for hundreds of targets of a human microRNA. PLoS Biol 2009; 7: e1000238.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Vogelmeier CF,
    2. Criner GJ,
    3. Martinez FJ, et al.
    Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med 2017; 195: 557–582.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Ernst P,
    2. Saad N,
    3. Suissa S
    . Inhaled corticosteroids in COPD: the clinical evidence. Eur Respir J 2015; 45: 525–537.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Molina-Pinelo S,
    2. Pastor MD,
    3. Suarez R, et al.
    MicroRNA clusters: dysregulation in lung adenocarcinoma and COPD. Eur Respir J 2014; 43: 1740–1749.
    OpenUrlAbstract/FREE Full Text
    1. Kim WJ,
    2. Lim JH,
    3. Hong Y, et al.
    Altered miRNA expression in lung tissues of patients with chronic obstructive pulmonary disease. Mol Cell Toxicol 2017; 13: 207–212.
    OpenUrl
  6. ↵
    1. Wang R,
    2. Xu J,
    3. Liu H, et al.
    Peripheral leukocyte microRNAs as novel biomarkers for COPD. Int J Chron Obstruct Pulmon Dis 2017; 12: 1101–1112.
    OpenUrl
  7. ↵
    1. Christenson SA,
    2. Brandsma CA,
    3. Campbell JD, et al.
    miR-638 regulates gene expression networks associated with emphysematous lung destruction. Genome Med 2013; 5: 114.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Lacedonia D,
    2. Palladino GP,
    3. Foschino-Barbaro MP, et al.
    Expression profiling of miRNA-145 and miRNA-338 in serum and sputum of patients with COPD, asthma, and asthma-COPD overlap syndrome phenotype. Int J Chron Obstruct Pulmon Dis 2017; 12: 1811–1817.
    OpenUrl
  9. ↵
    1. Qian Y,
    2. Mao ZD,
    3. Shi YJ, et al.
    Comprehensive analysis of miRNA-mRNA-lncRNA networks in non-smoking and smoking patients with chronic obstructive pulmonary disease. Cell Physiol Biochem 2018; 50: 1140–1153.
    OpenUrl
  10. ↵
    1. Faiz A,
    2. Steiling K,
    3. Roffel MP, et al.
    Effect of long-term corticosteroid treatment on microRNA and gene-expression profiles in COPD. Eur Respir J 2019; 53: 1801202.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Williams AE,
    2. Larner-Svensson H,
    3. Perry MM, et al.
    MicroRNA expression profiling in mild asthmatic human airways and effect of corticosteroid therapy. PLoS One 2009; 4: e5889.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Solberg OD,
    2. Ostrin EJ,
    3. Love MI, et al.
    Airway epithelial miRNA expression is altered in asthma. Am J Respir Crit Care Med 2012; 186: 965–974.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
View this article with LENS
Vol 53 Issue 4 Table of Contents
European Respiratory Journal: 53 (4)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
MicroRNAs in COPD: small molecules with big potential
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
MicroRNAs in COPD: small molecules with big potential
Brian D. Hobbs, Kelan G. Tantisira
European Respiratory Journal Apr 2019, 53 (4) 1900515; DOI: 10.1183/13993003.00515-2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
MicroRNAs in COPD: small molecules with big potential
Brian D. Hobbs, Kelan G. Tantisira
European Respiratory Journal Apr 2019, 53 (4) 1900515; DOI: 10.1183/13993003.00515-2019
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • The importance of patient's quality of life perception in PAH
  • Noninvasive strategies in COVID-19
  • Effectors of oxidative stress in the asthmatic lung
Show more Editorials

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society